What is BreachRx?
BreachRx operates as a specialized cybersecurity firm, delivering an intelligent incident response platform engineered to bolster operational resilience across the enterprise. The company's core technology automates the creation of tailored incident response plans, effectively guiding stakeholders through every phase of a security event. By streamlining these processes, BreachRx ensures that organizations maintain regulatory compliance while simultaneously shielding executive leadership from the personal liabilities often associated with data breaches and security failures. Its market position is defined by a focus on bridging the gap between technical security operations and high-level corporate governance.
How much funding has BreachRx raised?
BreachRx has raised a total of $21.5M across 2 funding rounds:
Angel/Seed
$6.5M
Series A
$15M
Angel/Seed (2024): $6.5M with participation from SYN Ventures and Overline
Series A (2025): $15M led by Silver Ventures, Ballistic Ventures, Overline, and SYN Ventures
Key Investors in BreachRx
SYN Ventures
SYN Ventures is a venture capital firm that specializes in investing in innovative companies within the cybersecurity, industrial security, national defense, privacy, regulatory compliance, and data governance sectors.
Overline
Overline is a founder-led venture capital firm that focuses on early-stage investments, providing hands-on support and key network introductions to its portfolio companies.
Ballistic Ventures
Ballistic Ventures is a specialized firm providing consulting and venture capital services exclusively for businesses operating within the cybersecurity industry.
What's next for BreachRx?
With the successful closure of this major enterprise-level funding, BreachRx is well-positioned to scale its operations and deepen its market penetration. The strategic capital will likely be deployed to enhance the platform's automation capabilities, expand its integration ecosystem, and grow its footprint within the global cybersecurity market. As the company transitions from its early-stage development phase into a period of rapid scaling, the focus will remain on refining its incident response architecture to meet the evolving needs of large-scale enterprises. Investors are expected to play a key role in providing the operational guidance necessary to navigate the competitive landscape of IT security and data governance.
See full BreachRx company page
